Posterior Transversus Abdominis Plane Block Versus Erector Spinae Plane Block as a Part of Multimodal Analgesia in Patients Undergoing Percutaneous Nephrolithotomy

NCT05448495 | Unknown Phase 4

• 1 other identifier: Posterior TAPB versus ERSPB
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

To compare the analgesic efficacy of posterior TAP block versus ESPB after PCNL surgery. The hypothesis is that posterior TAP block, as a part of multimodal analgesia, will reduce pain and opioid consumption like ESPB

Conditions

Analgesia

Keywords

Percutaneous nephrolithotomy; Erector spinae plane block; Transversus abdominis plane block

Outcome Measures

Primary Outcomes (1)

• The time to first call rescue analgesia

  From end of surgery till 24 hours

Study Arms (2)

Posterior TAP block

EXPERIMENTAL

Other: Posterior TAP block

ESPB

ACTIVE COMPARATOR

Other: ESPB

Interventions

Posterior TAP block OTHER

Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at the plane between internal oblique and transversus abdominis near the aponeurosis at the posterior axillary line.

Also known as: Posterior transversus abdominis plane block

Posterior TAP block

ESPB OTHER

Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at T9 erector spinae plane

Also known as: Erector spinae plane block

ESPB

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients scheduled for PCNL under general anesthesia
• ASA status I-II

You may not qualify if:

• Contraindications to regional block (coagulopathy, infection at the needle insertion site or known allergy to amide local anesthetics)
• Patient who has difficulty understanding the study protocol or patient refusal.
• Chronic respiratory disease patients.
• Diabetic patients.
• Body mass index (BMI) \> 30 Kg/m2
• Routine corticosteroids, pain medication, or anticonvulsant.
• Psychiatric diseases.

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut University

Asyut, 71515, Egypt

RECRUITING

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Fatma Nabil, M.D.

CONTACT

+201003633992; fatmanabil2012@aun.edu.eg

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: July 2, 2022
• First Posted: July 7, 2022
• Study Start: July 13, 2022
• Primary Completion: August 15, 2023
• Study Completion: September 15, 2023
• Last Updated: July 15, 2022

Record last verified: 2022-07

Locations

EG (1)